Author

Kelly Griffis

Observed name: K. Griffis

Observed institution: Fate Therapeutics (United States)

OpenAlex ID: A5022061360

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

2021 · Paolo Strati, Veronika Bachanova, et al. · Journal of Clinical Oncology · 35

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

2021 · Krish Patel, Veronika Bachanova, et al. · Blood · 20

938P A phase I/Ib study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

2025 · S. Chandana, A.B. El-Khoueiry, et al. · Annals of Oncology · 4

Works count: 3

Citation count: 59

H-index: 3

I10-index: 2